Bad visual outcome linked to clinical signs of AMD at time of cataract surgery

Article

Patients presenting with age-related macula degeneration (AMD) signs at cataract surgery have a longitudinally worse visual outcome compared to patients without AMD signs.

Patients presenting with age-related macula degeneration (AMD) signs at cataract surgery have a longitudinally worse visual outcome compared to patients without AMD signs, states a study in the Journal of Cataract and Refractive Surgery.

The longitudinal cohort study, led by Dr Eva Monestam, Department of Clinical Sciences and Ophthalmology, Faculty of Medicine, Norrlands University Hospital, Umeå University, Sweden, evaluated 810 patients.

Corrected distance visual acuity (CDVA) and clinical eye examinations were performed before and after surgery and 5 and 10 years after surgery for eligible patients. All participants were split into functional groups determined by postoperative signs of AMD and CDVA.

In AMD patients the rate of CDVA decline with age was faster compared to patients without comorbidity. In groups where CDVA was almost normal or reduced the slope of the visual acuity decline was similar.

In patients with no comorbidity there was a mean loss of 2.3 logMAR letters and 6.4 letters in AMD patients for each decade of increasing age. Better CDVA was seen in 75% of AMD patients 10 years postoperatively.

As a result of this, the study authors recommend that AMD patients are not discouraged from undergoing cataract surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.